Volume | 42,185 |
|
|||||
News | (1) |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Avita Medical Inc | RCEL | NASDAQ | Depository Receipt |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
11.26 | 11.14 | 11.7285 | 11.24 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume |
---|---|---|---|---|
620 | 42,185 | 11.40 | 480,764 | - |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
10:08:15 | 1 | 11.325 | USD |
Avita Medical Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.04B | 91.38M | - | 37.64M | -26.67M | -0.29 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
News Avita Medical
Date | Time | Source | Heading |
---|---|---|---|
12/04/2023 | 08:00 | GlobeNewswire Inc. | AVITA Medical to Host Investor Webinar Briefing |
11/21/2023 | 15:15 | GlobeNewswire Inc. | AVITA Medical to Present at the Piper Sandler 35th Annual.. |
11/21/2023 | 08:10 | IH Market News | Keep An Eye Out: Pre-Market Movers And Analyst.. |
11/20/2023 | 15:15 | GlobeNewswire Inc. | AVITA Medical Updates Full Year 2023 Guidance |
11/09/2023 | 15:09 | Edgar (US Regulatory) | Form 8-K - Current report |
11/09/2023 | 15:07 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
11/09/2023 | 15:01 | GlobeNewswire Inc. | AVITA Medical Reports Third Quarter Financial Results with.. |
11/09/2023 | 08:00 | GlobeNewswire Inc. | AVITA Medical Announces Distribution Partnership with.. |
10/23/2023 | 15:36 | Edgar (US Regulatory) | Form 8-K - Current report |
10/19/2023 | 15:05 | GlobeNewswire Inc. | AVITA Medical to Announce Third Quarter 2023 Financial.. |
10/18/2023 | 08:07 | Edgar (US Regulatory) | Form 8-K - Current report |
10/18/2023 | 08:04 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
RCEL Historical
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centres. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. |